Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Osteoporosis

25,470 views

Published on

Check www.medicaldump.com for medical documents, powerpoints, pdfs, x rays, CT scans . Daily new uploads!

Published in: Health & Medicine
  • Login to see the comments

Osteoporosis

  1. 1. Osteoporosis
  2. 2. Learning objectives : <ul><li>Burden of the disease. </li></ul><ul><li>Screening and treatment guidelines. </li></ul><ul><li>Bisphosphonates. </li></ul><ul><li>Controversial topics : Association of bisphosphonates with </li></ul><ul><ul><li>ONJ </li></ul></ul><ul><ul><li>Atypical femoral fractures </li></ul></ul><ul><ul><li>Atrial fibrillation. </li></ul></ul><ul><ul><li>Esophageal cancer. </li></ul></ul>
  3. 3. Burden of Disease <ul><li>10 million people in US have Osteoporosis </li></ul><ul><li>33 million people in US have Osteopenia. </li></ul><ul><li>Bone health and osteoporosis: Department of health & human services 2004. </li></ul>
  4. 4. Burden of Disease <ul><li>> 2 million fractures/year due to either. </li></ul><ul><ul><li>300,000 HIP fractures. </li></ul></ul><ul><ul><li>547,000 vertebral fractures. </li></ul></ul><ul><ul><li>135,000 pelvic factures. </li></ul></ul><ul><ul><li>Bone health and osteoporosis: Department of health & human services 2004. </li></ul></ul>
  5. 5. Burden of Disease : <ul><li>Hip fractures : </li></ul><ul><li>50 % Permanent impaired mobility. </li></ul><ul><li>25 % Loose skills to live independently. </li></ul><ul><li>Increased all cause mortality : first 3 months after hip fracture. </li></ul><ul><ul><li>1.2010 position statement of the North American Menopause Society. Menopause 2010. </li></ul></ul>
  6. 6. Annual incidence
  7. 7. Osteoporosis
  8. 8. Risk factors
  9. 9. Who to screen <ul><li>Women > 65 years. </li></ul><ul><li>Men > 70 years. </li></ul><ul><li>Postmenopausal women /men >50 years with clinical risk factors. </li></ul><ul><li>H/o fracture at age > 50 years. </li></ul><ul><li>Chronic steroid use. </li></ul>
  10. 11. Who to treat ? Prior h/o hip/vertebral # or T Score < -2.5 or T Score -1 to -2.5 & 10 yr risk (FRAX) : HIP # > 3 % or major osteoporotic # > 20 % Postmenopausal women /men > 50 yrs with
  11. 12. Calcium and vitamin D
  12. 13. Mainstay of treatment : <ul><li>Bisphosphonates </li></ul><ul><li>Approval in US for osteoporosis </li></ul><ul><li>Alendronate : 1995 </li></ul><ul><li>Risedronate : 2000 </li></ul><ul><li>Ibandronate : 2005 </li></ul><ul><li>Zoledronate : 2007. </li></ul>
  13. 14. Bone marrow precursors Osteoblasts Osteoclast Lining cells Stimulators of Bone Formation Fluoride PTH analogs Sr Ranelate (?) Inhibitors of Bone Resorption Estrogen, SERMs Bisphosphonates Calcitonin Inhibitors of RANKL Cathepsin K Therapeutic strategies
  14. 15. THE LANCET Vol 348 • December 7, 1996 Clinical Evidence
  15. 20. Taking Bisphosphonates
  16. 21. Contraindications
  17. 22. Duration of treatment
  18. 23. Cost factor <ul><li>Alendronate: $4 - $40/month </li></ul><ul><li>Risedronate : $60 - $120/month </li></ul><ul><li>Ibandronate (oral): $90 - $130/month </li></ul><ul><li>IV Ibandronate : $1300/year </li></ul><ul><li>IV Zoledronate : $1300/year </li></ul>
  19. 24. Hot topics
  20. 25. Osteonecrosis of jaw
  21. 26. ONJ <ul><li>Osteoporosis : </li></ul><ul><ul><li>Reporting rate 1/100,000 - 1/250.000. </li></ul></ul><ul><ul><li>True incidence may be higher. </li></ul></ul><ul><li>Malignancy/skeletal metastasis : </li></ul><ul><ul><li>Estd. Incidence: btw 1- 10 % </li></ul></ul>
  22. 27. Risk factors
  23. 28. Recommendations
  24. 29. Atypical fractures
  25. 30. Atypical fractures <ul><li>? Long term over suppression of bone turnover. </li></ul><ul><li>Incidence : 1 in 10,000. </li></ul><ul><li>Associated median treatment duration : 7 years. </li></ul><ul><li>Causality : long term bp/ atypical # unproven. </li></ul><ul><li>Further large scale studies needed. </li></ul>
  26. 31. Recommendations <ul><li>Educate physician/patient about Prodromal pain. </li></ul><ul><li>Evaluate with urgent X-Ray. </li></ul><ul><li>If negative, may consider MRI. </li></ul><ul><li>Stop BP’s if atypical fracture confirmed. </li></ul><ul><li> Shane et al. ASBMR task report. J Bone Miner Res. 2010 </li></ul>
  27. 32. Atrial fibrillation <ul><li>FDA recommends physicians to not alter their prescribing patterns while it continues to monitor post marketing reports of AF in such patients. </li></ul><ul><li>In v/o above and absence of definitive data : Benefits of treatment outweigh risks. </li></ul>
  28. 33. Esophageal cancer <ul><li>23 cases reported in last 2 decades. (Wysowski et al) </li></ul><ul><li>31 cases from Europe/Japan. </li></ul><ul><li>Median time from use to diagnosis : 1-2 yr. </li></ul><ul><li>Time from exposure inconsistent w/ causal relation. </li></ul><ul><li>Further studies needed. </li></ul>
  29. 34. Renal safety <ul><li>Safe for creatinine clearance > 30 -35 ml/min. </li></ul><ul><li>Lack of experience < 30 ml/min. </li></ul><ul><li>No data for use in ESRD. </li></ul><ul><li>Exact bone disease unknown unless biopsy. </li></ul><ul><li>Expert opinion: half the dose could be used for 3 years in ESRD once bone biopsy confirms osteoporosis. </li></ul>
  30. 35. Take home points <ul><li>Osteoporosis : significant burden of disease. </li></ul><ul><li>Main stay treatment : bisphosphonates. </li></ul><ul><li>? Duration of treatment : individualized. </li></ul><ul><li>More research needed to confirm association with ONJ, Subtrochanteric fracture. </li></ul><ul><li>Benefits of treatment outweigh risks in osteoporosis. </li></ul>

×